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Abstract
Background: Persisting fatigue has been reported to be a common complaint by individuals with connective tissue
disorders, including Osteogenesis imperfecta (OI). This controlled study evaluated in an adult OI population the
subjective experience of fatigue, affecting daily life. Sleep disturbances and chronic pain were examined as
hypothesized underlying factors.
Methods: This cross-sectional study analyzed the answers of 56 OI patients and 56 matched healthy controls
to a questionnaire, designed to evaluate levels of experienced fatigue and bodily pain, as well as the presence or absence
of symptoms related to sleep disturbances or sleep apnea. The relationships between fatigue, pain, and sleep
disturbances were evaluated with correlation analysis and regression analysis.
Results: Fatigue was reported by 96%, and daily pain by 87% of the individuals with OI. Notably, the level of
fatigue was similarly experienced by patient respondents and controls. In total, 95% of the patients and 77%
of the controls reported one to several sleep disturbance symptoms. These symptoms as well as previously
diagnosed sleep apnea were statistically significantly more prevalent in the patient group than in the controls
(p < 0.05). Likewise, the experienced bodily pain was statistically highly significantly more severe among the respondents
with OI (p < 0.001), and correlated with the reported fatigue.
Conclusions: In comparison with age-matched controls, adults with OI do not differ in experienced fatigue, unlike
hypothesized. Therefore, sleep disturbances, which based on the frequency of reported related symptoms and
previous sleep apnea diagnoses appear to be common in OI patients, may remain undiagnosed.
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Background
Osteogenesis imperfecta (OI) is a group of genetic disor-
ders of collagen synthesis, characterized by osteoporosis
and increased fracture tendency. OI affects approxi-
mately one in 10,000 people [1]. The clinical phenotype
of OI ranges from mild to severe, the mild type being
the most common. The original Sillence classification
designated the mild type as type I, the perinatally lethal
as type II, the severe, progressively deforming one as
type III, and the moderate one as type IV OI. [2, 3].
Despite the subsequent addition of histologically,
radiologically, and genetically distinct OI types, auto-
somal dominant mutations in COL1A1 and COL1A2
still account for approximately 90% of OI cases, and
the patients can be classified according to phenotypic
severity into the originally defined four types [4, 5].
Particularly in the moderate and severe forms of OI,
recurrent long-bone fractures and vertebral compression
fractures commonly result in skeletal deformities and
scoliosis, leading to short stature and physical disability.
Potential extra-skeletal manifestations of OI include
cardiovascular complications, pulmonary dysfunction,
neurologic problems, hearing loss, dental and occlusal
problems, pain, and fatigue. These co-morbidities, or a
fear of them, affect in several ways the patients’ quality of
life and functional ability [6–9].
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The Constitution of World Health Organization (WHO)
defines quality of life (QoL) as " individuals’ perception of
their position in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards and concerns”. QoL is a broad,
multidimensional concept that includes subjective evalua-
tions of both positive and negative aspects of life. OI affects
not only the QoL of the patient, but also that of a caregiver.
[8, 10, 11]. Previous research indicates that QoL of in-
dividuals with OI is negatively influenced by reduced
function due to tiredness and fatigue [8, 9]. Yet, the
prevalence and experience of fatigue in patients with
OI remains largely unexplored.
The aim of this cross-sectional study was to examine
in an adult OI population the subjective experience of
fatigue, affecting the patients’ everyday life, and to evalu-
ate in particular the level of pain and prevalence of self-
reported sleep disturbances, in order to assess their role
in excessive daytime sleepiness and fatigue. The hypoth-
esis is that patients with OI in comparison to healthy
controls report higher levels of both fatigue and pain,
and that pain, poor quality of sleep, and fatigue form a
vicious circle, impairing the QoL in OI.
Methods
The study was approved by the Research Ethics
Committee, Helsinki University Hospital. We con-
structed a custom questionnaire to assess the subject-
ive perception of fatigue, bodily pain, and sleep
disturbance symptoms. The questionnaire was posted
to the unselected 151 individuals, registered as patient
members of the Finnish Osteogenesis Imperfecta
Association. Inclusion criteria were diagnosis of OI,
and age of 16 years or above. Data were unavailable
of those Association members who did not return the
study questionnaire.
The survey was presented in the following sequence:
(1) Collection of general demographic and anthropometric
information, and subjective assessments on experienced
daily pain and fatigue (Table 1); (2) collection of specific in-
formation on symptoms related to fatigue and sleep distur-
bances (Table 2); and (3) qualitative analysis of subjective
reports on sleep related problems. Demographic data in-
cluded age and gender. Height and weight were enquired
as anthropometric information, and were used to calculate
the body mass index (BMI). Medical information addressed
OI type according to Sillence classification, primary means
of mobility, medical diagnosis of sleep apnea confirmed by
a polysomnography, and sleep disturbance symptoms. Pain
and fatigue were evaluated with a visual analogue scale
(VAS) from 0 to 10, where 0 is no pain/fatigue and 10 is
the worst possible pain/fatigue a person can imagine. To
establish the level of general physical impairment and func-
tional performance, ambulation was assessed as walking
without aid, walking with crutches, or wheelchair as a pri-
mary mode of mobility. The other variables, presented in
Table 2, were dichotomous (yes/no). This study used add-
itional qualitative analysis in order to gain insight into any
factor affecting sleep. Qualitative data were collected with
one open-ended question:” Do you have other sleep-related
problems?”. The same questionnaire, excluding anthropo-
metric information to increase unidentifiability of the par-
ticipants, was completed by 56 age- and gender-matched
volunteer controls without OI.
Descriptive data are given as means, ranges, frequen-
cies, and percentages. Height Z-score, reflecting the gen-
eral severity of the disorder [12], was calculated and
used in the statistical analysis. Pearson and Spearman
correlation coefficients were computed, according to the
distribution of the data, to assess the relationship be-
tween the variables in SPSS (IBM Corp. Released 2015.
IBM SPSS Statistics for Windows, Version 23.0.
Armonk, NY: IBM Corp.) The relationship between
sleep disturbance symptoms and fatigue was evaluated
by means of logistic regression analysis. Explanatory var-
iables were: diagnosed sleep apnea, snoring, pauses of
breathing during sleep, restless sleep, grinding of teeth
during sleep, recurrent nightmares, daytime sleepiness,
likelihood of dozing, dysphagia, difficulties of concentra-
tion, nocturia, and restless legs. Two-sample t-test and
chi-square test were used to compare the responses of
the patients and controls.
Results
The study group comprised 56 individuals with OI com-
pleting the survey (37% of those who received the ques-
tionnaire), and 56 healthy controls. Of the respondents,
39 had a classified OI, and of them 22 had type I (mild),
7 had type IV (moderate), and 10 had type III OI
(severe) (Table 1). Altogether 17 reported OI type to be
unknown. Of the respondents, 41 were females and 15
males. Their age distribution showed that middle-aged
and older individuals were active participants. In total,
20% of the respondents were in the age range of 16–
29 years old, 32% were in the age range of 30–49 years,
and 48% were aged 50 years or more. Mean age was
somewhat lower in those with severe OI (34 years) com-
pared to those with mild OI type (48 years). The major-
ity of the respondents walked unaided (55%). Those with
a more severe OI type utilized more often mobility aids.
Wheelchair was the primary means of mobility for 19
patients (34%).
Table 1 outlines the notable variation in the reported
current bodily pain and fatigue, with an average score of
5 for fatigue and 4 for pain for the patient group, corre-
sponding to a moderate intensity of fatigue and pain.
Fatigue and bodily pain were positively correlated
[r(55) = 0.29, p = 0.034]. No correlation between bodily
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pain and severity of OI was found, whereas fatigue
and severity of OI were negatively correlated [rs(38) =
−0.34, p = 0.037], indicating more reports of severe fa-
tigue among those with a mild OI type. In the youn-
gest patient age-group, the average score was 2 for
pain and 4 for fatigue. In the age-group of 30–
49 year-olds, the average score was 4 for pain and 5
for fatigue. In the oldest age group, the average scores
for pain and fatigue were 5.
Of the 54 participants with OI, who responded to the
dichotomous question about the presence or absence of
sleep apnea, eight (15%) had diagnosed sleep apnea and
used a positive airway pressure ventilator during sleep.
Yet of the remaining 46 without diagnosis of sleep
apnea, as many as 44 (96%) reported one or more sleep
disturbance related symptoms, daytime sleepiness (in
81%) being the most common one (Table 2). BMI and
height Z-score showed a negative correlation [r(56) =
−0.38, p = 0.004], implying that the more severe the OI
is, the higher the BMI. No correlation was found be-
tween height Z-score and presence of sleep apnea. In
contrast, BMI correlated positively with sleep apnea
[rs(54) = 0.28, p = 0.043]. The average scores for fatigue
and pain were similar in the eight patients with sleep
apnea diagnosis and those without a diagnosis (5 for
fatigue and 4 for pain).
Logistic regression analysis showed that in patients
with OI, a risk of higher levels of fatigue correlated with
daytime sleepiness (OR 3.8; 95%CI: 1.77–6.01; p = 0.001)
but the risk was not associated with the other sleep dis-
turbance symptoms. Those OI respondents with pauses
of breathing during sleep had significantly more fre-
quently diagnosed sleep apnea [rs(42) = 0.46, p = 0.002],
habit of snoring [rs(42) = 0.51, p = 0.001], and high likeli-
hood of dozing [rs(41) = 0.47, p = 0.002], as can be antici-
pated. In contrast, pauses of breathing and daytime
sleepiness did not show a correlation [rs(40) = 0.25,
p = 0.117].
Table 2 Prevalence of self-reported symptoms related to sleep-disturbances and sleep apnea among the respondents in the Osteogenesis
imperfecta patient cohort and controls
Number of patients
with symptoms (%)
N = 56
Number of controls
with symptoms (%)
N = 56
Significance of difference
between the study groups
(Chi-Square test)
Snoring 32/52 (62) 15/54 (28) 11.1 p = 0.001
Pauses of breathing during sleep 13/42 (31) 3/54 (6) 9.9 p = 0.002
Restless sleep 43/55 (78) 23/54 (43) 12.9 p < 0.001
Grinding of teeth during sleep 22/52 (42) 23/55 (42) Non-significant
Recurrent nightmares 16/50 (32) 2/55 (4) 13.3 p < 0.001
Daytime sleepiness 43/53 (81) 34/56 (61) 5.6 p = 0.018
Likelihood of dozing 14/52 (27) 5/56 (9) 6.3 p = 0.012
Dysphagia 17/51 (33) 1/55(2) 20.0 p < 0.001
Difficulties of concentration 24/50 (48) 6/54 (11) 16.6 p < 0.001
Nocturia 15/51 (29) 5/54 (9) 5.8 p = 0.016
Restless legs 19/51 (37) 8/54 (15) 10.0 p = 0.002
Diagnosed sleep apnea 8/54 (15) 1/55 (2) 5.4 p = 0.020
Table 1 Characteristics of the Osteogenesis imperfecta (OI) patient cohort, sub-grouped by OI type, and of the healthy controls
All Mild type Moderate type Severe type Unknown type Controls
Number of participants 56 22 7 10 17 56
Age range in years (mean) 16–75 (47) 19–75 (48) 26–55 (43) 18–52 (33) 16–71 (54) 16–75 (44)
Females/males 41/15 19/3 7/0 5/5 10/7 41/15
Height range in meters (mean) 0.80–1.75 (1.45) 1.47–1.75 (1.6) 0.80–1.65 (1.3) 0.80–1.33 (1.1) 1.10–1.75 (1.5) NA
Body mass index, mean 29 27 28 36 29 NA
Ambulation (no aid/crutches/wheelchair) 31/5/19 19/2/1 3/0/3 0/0/8 9/3/8 56/0/0
Bodily pain range (mean) 0–10 (4) 0–9 (4) 0–10 (4) 0–5 (2.3) 0–9 (4) 0–9(2)a
Fatigue range (mean) 0–10 (5) 2–10 (6) 2–8 (5.8) 1–7 (2.9) 0–8 (5) 0–8 (4)
Diagnosed sleep apnea 8 2 1 2 3 1
NA data not requested
athe difference, as compared to patient group mean, is statistically highly significant as p < 0.001
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OI patients were afflicted by statistically significantly
more severe bodily pain than the controls (t102 = 4.6, p <
0.001), whereas the level of experienced fatigue did not
differ significantly between the patient and control
groups. Among the controls, the average scores for fa-
tigue were similar in all age groups; 3.4 for those aged
29 years or below, 3.8 for those between 30 and 49 years,
and 3.7 for those aged 50 years or above. Of the con-
trols, 73% reported symptoms related to sleep distur-
bances. Statistically significantly more common in the
OI patient group than in the controls were snoring,
pauses of breathing during sleep, restless sleep, recurrent
nightmares, daytime sleepiness, likelihood of dozing,
dysphagia, difficulties of concentration, nocturia, and
restless legs, whereas grinding of teeth during sleep was
equally prevalent (Table 2).
In addition, answers to the open-ended question re-
vealed that eleven respondents with OI suffered from
frequent awakenings and four from difficulties in falling
asleep. Other reported sleep disturbances among the OI
patients were insomnia, nocturnal sweating, pain-
induced awakening, numbness of limbs and cranium, de-
pression, anxiety, and awakening by a feeling of falling
or choking. One healthy control detailed nocturnal
sweating, and another foot spasms as sleep-related dis-
ruptive events.
Discussion
This study found self-reported fatigue of various severity
in 96% of individuals with OI. Fatigue was similarly ex-
perienced by respondents of all ages. Altogether 76% of
the patients also reported symptoms that suggest the
presence of a sleep disturbance such as sleep apnea.
Daily pain was reported by 87% in the patient cohort.
The older patients reported more severe pain than the
younger ones. A subjective feeling of fatigue was inter-
estingly an equally current complaint in the control
group. Among the control respondents experiencing
fatigue, 86% also reported at least one symptom related
to sleep disturbances.
Fatigue is considered a more long-term condition than
somnolence [13]. It can have multiple physical and men-
tal causes. Fatigue appears to be a common finding in
patients with connective tissue disorders when com-
pared to the general population [14]. In patients with
Marfan and Ehlers-Danlos syndromes higher levels of fa-
tigue have been shown to be associated with chronic
pain [14, 15]. Similarly, in our patient cohort, the sever-
ities of fatigue and pain were expectedly positively corre-
lated. To our knowledge, the underlying causes of
fatigue, apart from physical fitness, had not previously
been studied in OI population.
Presumably low muscle function and level of physical
activity contribute to fatigue. Restrictions of physical
activity due to recurrent fractures, skeletal deformities
and pulmonary dysfunction may lead to decreased func-
tional ability, and furthermore aggravate fatigue in indi-
viduals with OI. In patients with mild OI (type I), no
pulmonary or cardiac symptoms at rest are normally
present. Previous studies, however, show that muscle
size, exercise tolerance and muscle strength are signifi-
cantly reduced in patients with OI [16–20]. On the other
hand, training has been shown to improve aerobic cap-
acity and muscle force, and to reduce the level of sub-
jective fatigue in children with mild and moderate OI
types [21]. In the light of previous studies, our finding of
lower average fatigue score in the individuals with severe
OI type, in contrast to those with mild type, was unex-
pected. It is still unclear how the fatigue and severity of
OI relate to each other. One possible explanation for our
seemingly contradictory finding could be that those indi-
viduals with mild OI type might have higher social
participation level than those with severe type. The
following hypothetical assumption would be that for in-
stance occupational participation alongside general
population demands considerable effort, leading to ex-
haustion. In addition, importantly, respondents with
mild OI were on average 14 years older than those with
severe type, which might contribute to their fatigue level
- although the reported fatigue among the control group
did not correlate with respondents’ age, emphasizing the
subjective aspect of fatigability. In patients with OI, we
found the severity of fatigue not correlating with the
presence of sleep disturbance symptoms other than day-
time sleepiness.
Chronic pain is intertwined with insomnia, psycho-
logical distress, difficulties in falling asleep, and frequent
arousal [22, 23]. Our results agree with these findings.
Insomnia, defined as a difficulty of falling asleep or stay-
ing asleep, was reported by 25% of the patient respon-
dents in our cohort in the answers to the open-ended
question. All of them were also suffering from a gen-
eralized pain. Interestingly however, the two patients
who declared having anxiety and depression reported
low scores for fatigue and pain. The answers obtained
from the open-ended question are consistent with the
trend of the quantitative data results, indicating a
considerable variability and subjectivity of the experi-
ence of pain and fatigue.
Individuals with varying severity of OI face several
QoL challenges across their lifespan. OI is conjoint with
high prevalence of co-morbidities in musculoskeletal,
auditory, pulmonary, and endocrine systems, as well as
dental problems and physical appearance alterations, all
of which are factors that can affect individuals’ QoL [9].
Earlier studies have revealed that adults with OI ex-
perience lower physical QoL but similar or higher
levels of mental QoL than the general population [24].
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The severity of OI has been found to correlate with wors-
ening of QoL. Experiencing pain, isolation, activity limita-
tions and participation limitations have been shown to
negatively affect QoL in OI. High scholastic competence
has been found in children and adults with OI. The risk of
fractures is an important concern faced by both adults
and children [11, 24]. This study found several of the pre-
viously mentioned QoL risk factors, such as experienced
pain and activity limitations in the OI population.
Sleep apnea is a sleep disorder characterized by pauses
in breathing or instances of shallow or infrequent
breathing during sleep. Sleep apnea is classified as cen-
tral, obstructive, or mixed. The diagnosis of sleep apnea
is based on the conjoint evaluation of clinical symptoms
and of the results of a polysomnography as apneic events
per hour of sleep [25]. Many of the symptoms of sleep
apnea are non-specific and can have other possible
causes. Sleep apnea affects roughly 3% of middle-aged
men and 2% of women in Finland [26]. In comparison, a
self-reported 14% prevalence of sleep apnea in an adult
OI population in US has been reported [9]. Similarly, in
our cohort, 15% of the respondents had a diagnosed
sleep apnea, confirmed by a polysomnography. General
factors predisposing to sleep apnea are obesity, snoring,
male gender, advanced age, structural abnormalities in
the nose and pharynx, nasal obstruction, small or reced-
ing lower jaw, functional factors such as small lung
capacity, and unstable ventilatory control during sleep
[27, 28]. In our OI cohort, BMI exceeded the WHO
diagnostic threshold for obesity (30 kg/m2) in 33%. The
use of BMI-measure can be misleading in individuals
with scoliosis and lower extremity deformities that lead
to loss of height, since the index is a height-related
measure. Location of fat deposition, especially anterolat-
eral to the upper airway, is more important than BMI in
regard to risk for obstructive sleep apnea (OSA) [29].
Findings on the association between BMI and excessive
daytime sleepiness are inconsistent in the literature
when the effect of OSA is not considered [30, 31].
Daytime sleepiness has been associated with depression,
nocturia, and metabolic factors more strongly than with
sleep-disordered breathing or sleep disruption per se.
Individuals with sleep apnea are not always pathologic-
ally sleepy [30, 32].
Snoring was reported by 62% of the OI respondents.
Snoring is a poor predictor of sleep apnea due to its
commonness in the general population. Of men 35–45%
and of women 15–28% report habitual snoring. The ab-
sence of snoring, however, makes apnea unlikely; only 6%
of apnea patients do not snore [29]. Insomnia and restless
legs syndrome are each clinically significant in 5–10% of
adults in general population, and an average incidence of
23% of respiratory-related leg movements has been docu-
mented in a sleep apnea cohort [33–35]. According to this
study, insomnia and restless legs are more frequent in OI
population than among unaffected peers.
This study presented with several strengths and limita-
tions. We used a mixed-method subjective self-evaluation
approach, using a non-validated detailed questionnaire for
not to miss any data that might help us to understand the
subjective experience of fatigue. The visual analogue scale
(VAS) is a simple and frequently used method for assess-
ment of intensity of pain [36]. Similarly, VAS has been
shown to be a valid and reliable instrument for the quanti-
tative assessment of fatigue in both healthy subjects and
in patients who complain of poor-quality sleep [37]. The
possible use of psychoactive drugs affecting sleep was not
documented. Without knowledge of the pharmaceutical
history of the patients, the association of possible bisphos-
phonate treatment and experienced bodily pain could not
be evaluated. The younger patients and those with severe
OI are more likely to have been treated with bisphospho-
nates that have been shown to be effective in reducing
bone pain and fatigue [38, 39]. The study population was
limited due to the rarity of OI. Although the disease
equally affects both genders, females were more active
than males in participating. Possible response bias cannot
be evaluated, as the investigators did not have access to
the entire target population’s characteristics and medical
history. It is likely that those with more symptoms were
more likely to participate. However, more than one third
of the target population responded and the frequency of
symptoms was very high, indicating that the studied
symptoms involve a significant proportion of the entire OI
population.
Conclusions
From the outcome of our investigation it is possible to
conclude that sleep disturbances are relatively common
symptoms in adults with OI, and more prevalent in adults
with OI than in the general population. Subjective feeling
of fatigue was equally experienced among the healthy con-
trols and in patients with OI. There are several possible
explanations for this result. Persistent fatigue that affects
day-to-day life was experienced by respondents of all ages.
The data gathered show that 76% of those OI patients suf-
fering from fatigue also reported symptoms that suggest
the presence of a sleep disturbance such as sleep apnea.
However, only 15% of the respondents with OI had a sleep
apnea diagnosis. Therefore, further studies of the true
prevalence, causes, and characteristics of sleep distur-
bances in OI population would be of interest.
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